[Study of clinical effect on treatment of chronic obstructive pulmonary disease in acute aggravated stage with Tanreqing injection and cell factor level].
OBJECTIVE
To make a study of the clinical effect on the treatment of chronic obstructive pulmonary disease in acute aggravated stage with Tanreqing Injection and the changes of the cell factor level.


METHODS
Eighty-seven cases of COPD patients in acute aggravated stage were chosen and divided into two groups at random. Forty-four cases in treatment group were given intravenous drip of Tanreqing (20 mL) with 5% G/NS (500 mL) once a day. Forty-three cases in control group were given intravenous drip Yanhuning injection (0.4 g) with 5% G/NS (500 mL) once a day. The courses of the treatment were both two weeks and the changes of TL-10, TNF-alpha and MPO were observed separately before and after the treatment.


RESULTS
The total effective rate in the treatment group was 94.31% while the control group 83.75%, which had significant difference (P<0.05). IL-10 level in both groups was comparatively lower than the healthy (P<0.01), while TNF-alpha and MPO was higher than the healthy (P<0.01). After the treatment, the TNF-alpha and MPO level in the treatment group decreased more greatly than those in the control groups (P<0.01) but the IL-10 increased a lot more than those in the control group and there existed remarkable difference (P<0.01).


CONCLUSIONS
The treatment of chronic obstructive pulmonary disease in acute aggravated stage with Tanreqing Injection can have noticeable effect, and can prohibit the release of above cell factors. It is also safe in clinical use without obvious side effects and has played an important role in the treatment of chronic obstructive pulmonary disease in acute aggravated stage.
Gong
Guoliang
G
School of Medicine, Jinhua College of Profession and Technology, Jinhua 321000, China. ggl6371@163.com
Li
Xin
X
D000328:Adult; D000368:Aged; D016207:Cytokines / Q000097:blood*; D064420:Drug-Related Side Effects and Adverse Reactions; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D016753:Interleukin-10 / Q000097:blood; D008297:Male; D008875:Middle Aged; D009195:Peroxidase / Q000097:blood; D029424:Pulmonary Disease, Chronic Obstructive / Q000097:blood* / Q000188:drug therapy* / Q000628:therapy; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
D016207:Cytokines; D004365:Drugs, Chinese Herbal; D014409:Tumor Necrosis Factor-alpha; C540817:tanreqing; D016753:Interleukin-10; D009195:Peroxidase